Alzamend Neuro Insider Trims Stake, Converts Series B Preferred
Rhea-AI Filing Summary
Milton C. Ault III, a director and 10% owner of Alzamend Neuro (ALZN), reported multiple transactions on Form 4. On 07/23/25, his affiliate Ault Lending, LLC converted 332.7553 Series B preferred shares into 143,429 common shares at an effective price of $2.32. The same day it sold 59,516 shares at an average $2.9502; a further 9,621 shares were sold on 07/24/25 at $2.9349.
Following the transactions, Ault Lending holds 82,552 common shares. Including other entities controlled by Mr. Ault (direct 1,843; Ault Life Sciences Inc. 11,068; Ault Life Sciences Fund LLC 61), his aggregate beneficial ownership is ≈95,524 common shares. Derivative positions remain significant: 1,767.2447 Series B preferred shares (no expiration) and 45,569 warrants with strike prices ranging from $108 to $4,050 expiring 2025-2029.
The filing shows a net reduction of roughly 69,137 shares (-42% of the 07/23 conversion) in Ault Lending’s indirect stake. While the conversion eliminates some preferred stock—simplifying the capital structure—the concurrent sales by a large insider can be viewed as a bearish signal for near-term sentiment.
Positive
- Conversion of Series B preferred into common stock reduces preferred overhang and simplifies ALZN’s capital structure.
Negative
- Sale of 69,137 common shares by a 10% owner/director signals potential short-term bearish sentiment.
Insights
TL;DR: 10% owner converts preferred, sells ~69k shares—slightly bearish.
The combination of a preferred-to-common conversion and immediate partial disposition indicates liquidity taking by a key insider. Although removal of preferred shares marginally cleans up the equity stack, the disposition equates to selling ~42 % of the shares just received, suggesting limited confidence in short-term upside. Remaining derivative exposure (1.77k preferred; 45.6k warrants) still aligns Mr. Ault with long-term optionality, but the market often views insider selling—especially by a control shareholder—as a negative price catalyst. Overall impact: modestly negative.
TL;DR: Insider’s mixed actions—capital-structure simplification vs. share sales—net to cautious outlook.
Conversion of Series B preferred improves transparency and may reduce dividend or voting complexity, a governance positive. However, rapid secondary-market sales weaken the alignment narrative typically expected from directors owning >10 %. Investors should watch for further sales or 13D amendments that could lower ownership below critical thresholds, potentially altering control dynamics.
Insider Trade Summary
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Sale | Common Stock | 9,621 | $2.9349 | $28K |
| Conversion | Series B Convertible Preferred Stock | 332.755 | $1,000.00 | $333K |
| Conversion | Common Stock | 143,429 | $2.32 | $333K |
| Sale | Common Stock | 59,516 | $2.9502 | $176K |
| holding | Common Stock Purchase Warrants | -- | -- | -- |
| holding | Common Stock Purchase Warrants | -- | -- | -- |
| holding | Common Stock Purchase Warrants | -- | -- | -- |
| holding | Common Stock Purchase Warrants | -- | -- | -- |
| holding | Common Stock | -- | -- | -- |
| holding | Common Stock | -- | -- | -- |
| holding | Common Stock | -- | -- | -- |
Footnotes (1)
- Represents shares of common stock received upon conversion of Series B convertible preferred stock ("Series B Preferred"). Ault Lending, LLC ("Ault Lending"), is a wholly-owned subsidiary of Hyperscale Data, Inc. ("HSD"). Mr. Ault, the Executive Chairman of HSD, is deemed to have voting and investment power with respect to the securities held of record by Ault Lending. Mr. Ault has sole voting and investment power with respect to the securities held of record by Ault Life Sciences, Inc. Mr. Ault has sole voting and investment power with respect to the securities held of record by Ault Life Sciences Fund, LLC. The Conversion Price of the Series B Preferred is subject to adjustment as set forth in that certain of Designation of Preferences, Rights and Limitations of the Series B Convertible Voting Preferred Stock. The shares of Series B Preferred have no expiration date. Mr. Ault, the Executive Chairman of HSD, is deemed to have voting and investment power with respect to the securities held of record by HSD.
